Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, has been hailed as a revolutionary tool in ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

Biohacking has moved from niche experiments to a global movement reshaping how we think about human potential. With ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

EST Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics (CRSP) todayMaximize Your Portfolio with Data Driven ...